$259 Thousand is the total value of UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's 18 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 78.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBRE | Sell | JPM BETABLDRS MSCI US REITetfs | $216,221 | -1.7% | 2,560,948 | -3.5% | 83.60% | -1.1% |
| EOCWU | ELLIOTT OPPORTUNITY II CORP | $20,680 | +1.1% | 2,000,000 | 0.0% | 8.00% | +1.7% | |
| IMTX | IMMATICS NV | $8,048 | +67.2% | 697,431 | 0.0% | 3.11% | +68.3% | |
| TXN | TEXAS INSTRUMENTS INC | $5,761 | -3.2% | 32,000 | 0.0% | 2.23% | -2.6% | |
| VT | VANGUARD TOT WORLD STK ETFetfs | $2,869 | +5.3% | 29,585 | 0.0% | 1.11% | +6.0% | |
| Sell | HASHICORP INC | $2,204 | -12.1% | 84,182 | -1.7% | 0.85% | -11.5% | |
| BOND | PIMCO ACTIVE BOND EXCHANGE-T | $1,420 | -1.3% | 15,502 | 0.0% | 0.55% | -0.5% | |
| DNLI | New | DENALI THERAPEUTICS INC | $1,077 | – | 36,513 | +100.0% | 0.42% | – |
| MNDY | New | MONDAY.COM LTD | $126 | – | 738 | +100.0% | 0.05% | – |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $111 | +56.3% | 245,678 | 0.0% | 0.04% | +59.3% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $82 | -5.7% | 35,714 | 0.0% | 0.03% | -3.0% | |
| TFFP | TFF PHARMACEUTICALS INC | $10 | -33.3% | 22,066 | 0.0% | 0.00% | -33.3% | |
| ADBE | New | ADOBE INC | $7 | – | 14 | +100.0% | 0.00% | – |
| MA | New | MASTERCARD INC | $7 | – | 18 | +100.0% | 0.00% | – |
| V | New | VISA INC | $7 | – | 29 | +100.0% | 0.00% | – |
| POR | PORTLAND GENERAL ELECTRIC CO | $6 | 0.0% | 118 | 0.0% | 0.00% | 0.0% | |
| AAPL | New | APPLE INC | $2 | – | 11 | +100.0% | 0.00% | – |
| NVDA | New | NVIDIA CORP | $3 | – | 7 | +100.0% | 0.00% | – |
| PG | Exit | PROCTER & GAMBLE CO/THE | $0 | – | -18 | -100.0% | -0.00% | – |
| BR | Exit | BROADRIDGE FINANCIAL SOLUTIONS | $0 | – | -45 | -100.0% | -0.00% | – |
| PLXP | Exit | PLX PHARMA INC | $0 | – | -62,673 | -100.0% | -0.00% | – |
| HESM | Exit | HESS MIDSTREAM LPlp - public equity | $0 | – | -340 | -100.0% | -0.00% | – |
| DE | Exit | DEERE & CO | $0 | – | -63 | -100.0% | -0.01% | – |
| CDAK | Exit | CODIAK BIOSCIENCES INC | $0 | – | -847,108 | -100.0% | -0.06% | – |
| APEN | Exit | APOLLO ENDOSURGERY INC | $0 | – | -15,601 | -100.0% | -0.06% | – |
| BEAM | Exit | BEAM THERAPEUTICS INC | $0 | – | -59,839 | -100.0% | -0.70% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-04
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEXAS INSTRUMENTS INC | 41 | Q3 2023 | 31.2% |
| PORTLAND GENERAL ELECTRIC CO | 38 | Q3 2023 | 0.0% |
| LEXICON PHARMACEUTICALS INC | 33 | Q3 2023 | 1.7% |
| AEGLEA BIOTHERAPEUTICS INC | 27 | Q2 2023 | 11.0% |
| APOLLO ENDOSURGERY INC | 24 | Q1 2023 | 5.6% |
| PLX PHARMA INC | 23 | Q1 2023 | 1.7% |
| VANGUARD MSCI EMERGING MKTS | 22 | Q2 2019 | 10.3% |
| VANGUARD ENERGY ETF | 22 | Q2 2019 | 8.7% |
| VANGUARD S&P 500 ETF | 21 | Q3 2023 | 11.8% |
| VANGUARD MSCI EAFE ETF | 20 | Q2 2019 | 13.1% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Taysha Gene Therapies, Inc. | September 24, 2021 | 1,156,255 | 3.0% |
| ZIOPHARM ONCOLOGY INC | February 12, 2016 | 9 | 0.0% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-17 |
| 4 | 2024-06-12 |
| 4 | 2024-06-07 |
| 4/A | 2024-05-14 |
| 4 | 2024-05-01 |
| 3 | 2024-04-30 |
| 13F-HR | 2024-04-30 |
| 144 | 2024-04-29 |
| SC 13G | 2024-03-05 |
| 13F-HR | 2024-02-28 |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.